Study of two experimental drugs for non-squamous lung cancer after EGFR inhibitor failure
This trial tests a combination of two new drugs (SKB264 and SKB118) for people with a specific type of lung cancer (non-squamous non-small cell) that has an EGFR mutation and has stopped responding to standard EGFR inhibitor treatment. The goal is to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called non-squamous non-small cell lung cancer that is advanced (stage IIIB/IIIC or IV) and cannot be removed with surgery or treated with radiation.
- Your tumor has a change (mutation) in the EGFR gene, which is known to respond to EGFR inhibitor drugs.
- You have already tried an EGFR inhibitor drug for your advanced cancer, and it stopped working.
- You are able to provide a sample of your tumor tissue for testing.
- You have at least one tumor that can be measured on scans (per RECIST criteria).
- You are generally able to care for yourself (ECOG performance status 0 or 1) and are expected to live at least 12 more weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (JS207) that targets both PD-1 and VEGF pathways, given alone or with other treatments, for people with advanced non-small cell lung cancer that has a specific gene change and has stopped responding to targeted therapy (TKI). The goal is to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a combination of two new drugs, SKB264 and SKB118, for people with advanced non-small cell lung cancer. It may be an option if your cancer does not have the EGFR or ALK gene changes and you are in relatively good health.
This trial tests a new combination of two medications (SKB264 and anlotinib) for people with advanced non-small cell lung cancer that has spread to the liver and no longer responds to a standard pill called an EGFR-TKI. The goal is to see if this combination can shrink tumors and help people live longer.
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
This trial tests a new drug called SKB571 in people with advanced non-small cell lung cancer. The goal is to see if it can help shrink tumors or slow cancer growth.
This study tests an experimental drug called SKB118 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth.
Hear when a new Non-squamous Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.